Literature DB >> 6872257

Urinary excretion of deuterated metabolites in patients with tyrosinemia type I after oral loading with deuterated L-tyrosine.

S K Wadman, M Duran, D Ketting, L Bruinvis, F J van Sprang, R Berger, G P Smit, B Steinmann, J V Leonard, P Divry, J P Farriaux, B Cartigny.   

Abstract

1. The metabolic fate of orally given deuterated L-tyrosine, 50 mg/kg body weight, was investigated in seven patients with tyrosinemia type I in order to obtain evidence that the primary defect is at the level of fumarylacetoacetase. 2. The absence of fumarylacetoacetase could be proved in liver biopsy specimens obtained from four patients. 3. All patients excreted deuterated succinylacetoacetate and deuterated succinylacetone was detected in six out of seven. The total amount of these compounds was rather low; maximal 8.3% of the dose. The peak of the excretion occurred 3-6 h after loading, indicating an endogenous formation of the metabolites. 4. All patients excreted deuterated 4-hydroxyphenyl acids, probably reflecting secondary 4-hydroxyphenylpyruvate dioxygenase deficiency connected with liver damage. 5. No evidence for other secondary routes of tyrosine metabolism was found.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6872257     DOI: 10.1016/0009-8981(83)90120-1

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  4 in total

Review 1.  Tyrosinaemia type I: orthotopic liver transplantation as the only definitive answer to a metabolic as well as an oncological problem.

Authors:  F J van Spronsen; R Berger; G P Smit; J B de Klerk; M Duran; C M Bijleveld; H van Faassen; M J Slooff; H S Heymans
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

2.  Persistent succinylacetone excretion after liver transplantation in a patient with hereditary tyrosinaemia type I.

Authors:  M Tuchman; D K Freese; H L Sharp; C B Whitley; M L Ramnaraine; R A Ulstrom; J S Najarian; N Ascher; N R Buist; A B Terry
Journal:  J Inherit Metab Dis       Date:  1985       Impact factor: 4.982

3.  Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers.

Authors:  M G Hall; M F Wilks; W M Provan; S Eksborg; B Lumholtz
Journal:  Br J Clin Pharmacol       Date:  2001-08       Impact factor: 4.335

4.  Clinical features and diagnostic approach in type I tyrosinaemia in an infant with cytomegaly virus infection and bacterial sepsis.

Authors:  M Wabitsch; F Pohlandt; D Leupold; R Berger; E Mönch; E Heinze; W Teller
Journal:  Eur J Pediatr       Date:  1993-04       Impact factor: 3.183

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.